Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Peoples Republic of China.
J Vasc Surg. 2011 Jan;53(1):156-64. doi: 10.1016/j.jvs.2010.06.170.
Studies have indicated that ginsenoside Rb1 and ghrelin could both prevent homocysteine (Hcy)-induced endothelial dysfunction through the endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) mechanism. This study investigated whether endogenous ghrelin mediates the endothelial protection of ginsenosidee Rb1 through in vitro and in vivo experiments.
Rats were randomized into a control group, a hyperhomocysteine (HHcy) model group with a high methionine diet, a ginsenosides (GS) group, and HHcy plus GS group. Plasma ghrelin was detected by enzyme-linked immunosorbent assay. Aortic rings for control and HHcy groups were treated with ghrelin or not. Endothelium-dependent vasodilatation function was evaluated by the aortic ring assay, and the structural changes were visualized by hematoxylin and eosin staining. Human umbilical vein endothelial cells (HUVECs) were cultured, and the experimental conditions were optimized according to NO production. After treatment, the NO, ghrelin, and von Willebrand factor (vWF) levels in the media were detected and analyzed with linear regression. Ghrelin and eNOS expression were observed by cell immunohistochemical staining. Ghrelin receptor antagonist was used to detect the mechanism of ginsenoside Rb1 on NO production, which was reflected by diacetylated 4,5-diaminofluorescein-2 diacetate fluorescence.
In vivo experiments demonstrated that plasma ghrelin levels in the HHcy group were significantly elevated vs controls (P < .05) and were significantly increased in the HHcy plus GS group (P < .01). Compared with control, endothelium-dependent vasodilatation function was greatly reduced in the HHcy group (P < .01), which was significantly increased in HHcy plus ghrelin group compared with HHcy group (P < .01). The arterial walls of HHcy group exhibited characteristic pathologic changes, which were repaired in HHcy plus ghrelin group. In vivo, compared with Hcy (200 μM) group, HUVECs pretreated with ginsenoside Rb1 (10 μM) for 30 minutes showed significant increases in NO and ghrelin levels and evident reduction in vWF levels. Linear regression analysis demonstrated that ghrelin levels were significantly positively correlated with NO levels and significantly negatively correlated with vWF levels. The addition of Rb1 to Hcy also greatly reversed Hcy-induced downregulation of ghrelin and eNOS expression. Ghrelin inhibition significantly abolished the upregulation of NO levels induced by Rb1.
Ghrelin can prevent Hcy-induced vascular endothelial dysfunction and structural damage. The compensatory elevation of plasma ghrelin levels in an Hcy-induced endothelial injury model may be a protective response. Ginsenoside Rb1 can significantly stimulate the ghrelin endocrine to inhibit endothelial injury. Ginsenoside also upregulates the NO signaling pathway reduced by Hcy through the ghrelin molecular mechanism.
有研究表明,人参皂苷 Rb1 和 ghrelin 均可通过内皮型一氧化氮合酶(eNOS)/一氧化氮(NO)机制预防同型半胱氨酸(Hcy)诱导的内皮功能障碍。本研究通过体外和体内实验探讨内源性 ghrelin 是否通过 ginsenosidee Rb1 介导内皮保护作用。
大鼠随机分为对照组、高蛋氨酸饮食诱导的高同型半胱氨酸血症(HHcy)模型组、人参皂苷(GS)组和 HHcy 加 GS 组。酶联免疫吸附试验检测血浆 ghrelin 水平。用 ghrelin 处理或不处理主动脉环,评估控制组和 HHcy 组的内皮依赖性血管舒张功能,并用苏木精和伊红染色观察结构变化。培养人脐静脉内皮细胞(HUVECs),并根据 NO 产生情况优化实验条件。处理后,检测并分析培养基中 NO、ghrelin 和血管性血友病因子(vWF)水平,用细胞免疫组化染色观察 ghrelin 和 eNOS 表达。用 ghrelin 受体拮抗剂检测 ginsenoside Rb1 对 NO 产生的作用机制,通过二乙酰化 4,5-二氨基荧光素-2 二乙酸酯荧光反映。
体内实验表明,HHcy 组血浆 ghrelin 水平明显高于对照组(P<0.05),HHcy 加 GS 组明显高于 HHcy 组(P<0.01)。与对照组相比,HHcy 组内皮依赖性血管舒张功能明显降低(P<0.01),而 HHcy 加 ghrelin 组明显高于 HHcy 组(P<0.01)。HHcy 组的动脉壁呈现出特征性的病理变化,而 HHcy 加 ghrelin 组得到修复。体内,与 Hcy(200 μM)组相比,用 10 μM 人参皂苷 Rb1 预处理 30 分钟的 HUVECs 中,NO 和 ghrelin 水平显著升高,vWF 水平显著降低。线性回归分析表明,ghrelin 水平与 NO 水平呈显著正相关,与 vWF 水平呈显著负相关。Rb1 的添加还极大地逆转了 Hcy 诱导的 ghrelin 和 eNOS 表达下调。ghrelin 抑制显著消除了 Rb1 诱导的 NO 水平升高。
ghrelin 可预防 Hcy 诱导的血管内皮功能障碍和结构损伤。Hcy 诱导的内皮损伤模型中血浆 ghrelin 水平的代偿性升高可能是一种保护反应。人参皂苷 Rb1 可通过 ghrelin 内分泌显著刺激抑制内皮损伤。人参皂苷还通过 ghrelin 分子机制上调 Hcy 降低的 NO 信号通路。